Description

Tipranavir is a potent, non-peptidic protease inhibitor specifically designed for the treatment of Human Immunodeficiency Virus (HIV) infection. Its core value proposition lies in its unique mechanism of action, which is effective against HIV strains that have developed resistance to other protease inhibitors. This product is essential for pharmaceutical manufacturers and research institutions engaged in the development and production of advanced antiretroviral therapies, particularly for treatment-experienced patients. Tipranavir CAS NO 191150-83-1 represents a critical component in the global fight against drug-resistant HIV.

Application

• Active Pharmaceutical Ingredient (API): Primary use as the key active component in the formulation of antiretroviral medications for HIV-1 treatment.
• Drug Development & Research: Serves as a reference standard and key intermediate in pharmaceutical R&D for novel HIV therapies and combination drug studies.
• Combinatorial Therapy: Used in fixed-dose combination drugs, often co-administered with ritonavir to boost its pharmacokinetic profile.
• Clinical Research Material: Utilized in preclinical and clinical trials to study efficacy, dosage, and safety profiles in treatment-resistant patient populations.
• Pharmacology Studies: Employed in academic and industrial laboratories to investigate mechanisms of viral resistance and protease inhibition.

Basic Information

Product Name	Tipranavir
CAS No.	191150-83-1
Molecular Formula	C₃₁H₃₃F₃N₂O₅S
Molecular Weight	602.67 g/mol
Synonyms	PNU-140690; TPV; Aptivus® (Trade Name); 4-Hydroxy-5,6-dihydro-4-[[1-[2-(1-methylethyl)-4-thiazolyl]-3-(trifluoromethyl)benzyl]amino]-2H-pyran-2-one; 5,6-Dihydro-4-hydroxy-2H-pyran-2-one Tipranavir Derivative; (2R)-N-[(1S)-1-Benzyl-2-[(2S,3S)-3-hydroxy-4-[[(3S)-3-isopropyl-5,6-dihydro-4-oxo-2H-pyran-2-yl]amino]-2-(1-methylethyl)butyl]-2-oxoethyl]-3-methyl-2-(methylamino)butanamide
EINECS	Contact for details

Quality Control

Our Tipranavir is manufactured under strict quality systems to ensure it meets the high-purity standards required for pharmaceutical applications. Each batch undergoes comprehensive analytical testing, including HPLC for assay and purity, identification by spectroscopic methods, and stringent control of related substances and residual solvents. A Certificate of Analysis (COA) documenting full compliance with in-house specifications is provided with every shipment. We support development projects with material suitable for use under cGMP guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.